| 22.425 0.005 (0.02%) | 09-21 15:59 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 28.24  |
1-year : | 29.67 |
| Resists | First : | 24.17 |
Second : | 25.4 |
| Pivot price | 23.43 |
|||
| Supports | First : | 22.19 |
Second : | 18.46 |
| MAs | MA(5) : | 22.68 |
MA(20) : | 23.73 |
| MA(100) : | 23.83  |
MA(250) : | 23.28 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 5.6 |
D(3) : | 6.5 |
| RSI | RSI(14): 36.6 |
|||
| 52-week | High : | 27.97 | Low : | 18.47 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ELAN ] has closed above bottom band by 15.2%. Bollinger Bands are 18.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 22.63 - 22.78 | 22.78 - 22.91 |
| Low: | 21.82 - 22.01 | 22.01 - 22.18 |
| Close: | 22.13 - 22.43 | 22.43 - 22.7 |
Elanco Animal Health, a firm dedicated to animal well-being, creates, produces, and commercializes a diverse array of solutions for both companion animals and livestock. For household pets, the company provides preventative health solutions, including parasiticides and vaccinations, designed to guard against common ailments like worms, fleas, and ticks, with notable brands such as Seresto, Advantage, Advantix, and Advocate. Additionally, Elanco supplies therapeutic treatments for canine and feline conditions including pain, osteoarthritis, ear infections, cardiovascular issues, and dermatological problems, marketed under labels like Galliprant and Claro. Its portfolio for agricultural animals encompasses vaccines, antibiotics, parasiticides, and other essential products for poultry and aquaculture farming. This segment also features nutritional supplements such as enzymes, probiotics, and prebiotics to support animal health and growth. Furthermore, the company offers a comprehensive suite of products for ruminant and swine operations, comprising vaccines, antibiotics, implants, and parasiticides, often recognized by brands like Rumensin and Baytril. Elanco distributes its offerings through various channels, including independent distributors, veterinary clinics, and a broad spectrum of farm animal producers, from cattle and dairy farms to pig, poultry, and aquaculture enterprises. Established in 1954, Elanco Animal Health Incorporated maintains its corporate headquarters in Greenfield, Indiana.
Mon, 21 Sep 2026
Elanco Animal Health (ELAN) Stock Analysis: Unveiling 39% Upside Potential in the Thriving Animal Health Sector - DirectorsTalk Interviews
Fri, 18 Sep 2026
Precision Trading with Elanco Animal Health Incorporated (ELAN) Risk Zones - Stock Traders Daily
Thu, 17 Sep 2026
Elanco to Participate in BofA Securities Global Healthcare Conference 2026 - PR Newswire
Tue, 15 Sep 2026
Expanding Tick and Itch Season Supports Momentum in Elanco Innovation, Meeting Pet Owner Demand for Health and Wellness Care - CSRwire
Mon, 14 Sep 2026
Is Elanco Animal Health (ELAN) Undervalued As Growth Expectations Meet A Recent Pullback? - Yahoo Finance
Thu, 10 Sep 2026
Elanco to Participate in Morgan Stanley 24th Annual Global Healthcare Conference - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 499 (M) |
| Shares Float | 495 (M) |
| Held by Insiders | 1.2 (%) |
| Held by Institutions | 115.4 (%) |
| Shares Short | 29,720 (K) |
| Shares Short P.Month | 35,820 (K) |
| EPS | -0.41 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 13.18 |
| Profit Margin | -4 % |
| Operating Margin | 8.6 % |
| Return on Assets (ttm) | 1.5 % |
| Return on Equity (ttm) | -3 % |
| Qtrly Rev. Growth | 10.1 % |
| Gross Profit (p.s.) | 5.56 |
| Sales Per Share | 10.05 |
| EBITDA (p.s.) | 2.02 |
| Qtrly Earnings Growth | 440.5 % |
| Operating Cash Flow | 617 (M) |
| Levered Free Cash Flow | 827 (M) |
| PE Ratio | -54.7 |
| PEG Ratio | 4 |
| Price to Book value | 1.7 |
| Price to Sales | 2.23 |
| Price to Cash Flow | 18.15 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|